HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19

This article was originally published here

HFB30132A is said to have been discovered, engineered, and developed in less than six months by the US-based HiFiBiO Therapeutics. The company said that its partnership with ABL

The post HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply